CC 90006

Drug Profile

CC 90006

Alternative Names: CC-90006

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaptysBio
  • Developer Celgene Corporation
  • Class
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Autoimmune disorders

Most Recent Events

  • 08 Nov 2017 Celgene plans a phase I trial for Psoriasis in USA (NCT03337022)
  • 01 Nov 2016 Phase-I clinical trials in Autoimmune disorders (In volunteers) in USA (SC) (NCT02934269)
  • 14 Oct 2016 Celgene Corporation plans a phase I trial in Healthy volunteers in USA (SC) (NCT02934269)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top